Opinion · 19 Sep 2025
Conference abstractPublished 27 Jul 2021
Identify non-mutational TP53 loss of function in human cancers
United States
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Disruption of gene function is not solely caused by genetic alteration in cancer. A gene with an intact DNA sequence can also compromise its function by epigenomic, transcriptomic, and proteomic level dysregulations (i.e., non-mutational inactivations). Non-mutational inactivations are prevalent in cancers but, due to the heterogenetic causes, cannot be detected by the DNA-sequencing, immunohistochemical staining or any other single assay alone. Therefore, they would become a significant impediment for molecular diagnostics, clinical management, and treatment selection for cancer patients. We hypothesized that when TP53 is functionally impaired, either due to genetic or non-genetic causes, the expression of downstream target genes would be significantly altered, and that such expression alteration, in turn, can be used to predict the status (i.e., normal or loss-of-function/LoF) of TP53. To identify non-mutational inactivations of p53, we first define p53 target genes through a comprehensive literature review and meta-analysis. Then, we build an SVM model using the composite expression scores of these target genes as features, and using the “non-cancerous normal tissues” (assuming p53’s tumor suppressor function is normal in this group) and “TP53truncating tumor samples” (assuming p53’s tumor suppressor function is lost in this group) as training datasets. Results: Using 5-fold cross-validation, we demonstrated the superior performance of our SVM models (average AUC = 0.995, F1-score = 0.989, recall = 0.992) in TCGA LUNG and BRCA cohorts. When applying our SVM model to TP53WT tumor samples, we found 87% of BRCA and 94% of LUNG samples were predicted to be LoF (termed as TP53WT-LoF). These TP53WT-LoF patients exhibited distinct genomic and clinical characteristics from the other TP53WT patients. Specifically, TP53WT-LoF patients have significantly higher tumor mutation burden, fraction of genome with copy number variations, aneuploidy score and hypoxia score, consistent with p53’s function as a central regulator of DNA damage repair and cellular stress response. In addition, TP53WT-LoF patients with lung cancer have significantly shortened overall survival, compared to those real TP53WT patients. Further analyses revealed that MDM2/MDM4 amplifications are significantly enriched in TP53WT-LoF patients, partially and mechanistically explained the p53 loss-of-function.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Medicinal & Aromatic Plants.
Perspective · 18 Sep 2025
Bioactive Compounds from Medicinal Plants and Their Therapeutic Applications
Perspective · 18 Sep 2025
Conservation Strategies for Endangered Medicinal Plant Species
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalMedicinal & Aromatic Plants
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Liguo Wang”

